by JAMA Network
Interviews with authors of articles from JAMA Ophthalmology. JAMA Ophthalmology, published continuously since 1869, is an international, peer-reviewed ophthalmology and visual science journal. Covering research, science, & clinical practice in ophthalmology and vision science.
Language
🇺🇲
Publishing Since
11/14/2011
Email Addresses
1 available
Phone Numbers
0 available
March 6, 2025
<p>Interview with Arshad M. Khanani, MD, author of Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. Hosted by Neil Bressler, MD.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2025.0006?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema</a></li> </ul>
February 20, 2025
<p>Interview with Harry A. Quigley, MD, author of Shedding LiGHT on Selective Laser Trabeculoplasty, and guest Michael A. Kass, MD, Washington University School of Medicine in St Louis. Hosted by Neil M. Bressler, MD.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2025.0004?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Shedding LiGHT on Selective Laser Trabeculoplasty</a></li> </ul>
January 30, 2025
<p>Interview with Bradley J. Katz, MD, PhD, author of Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. Hosted by Neil Bressler, MD.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.6058?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide</a></li> </ul>
American Academy of Ophthalmology
American Academy of Ophthalmology
Jonathan L. Prenner, MD
Retina Today
MayoClinicOphthalmology
Ben Young and Andrew Pouw
Cataract and Refractive Surgery Today
Cataract Coach with Uday Devgan MD
Modern Optometry
Modern Optometry
Formula 1
Dr. David Kading
Roya Habibi OD & Sheila Morrison OD
Dr. Jim Dahle of the White Coat Investor
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.